Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
Open Access
- 16 March 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (7), 1157-1162
- https://doi.org/10.1038/sj.bjc.6605590
Abstract
Malignant melanoma, generally described as incurable, is notoriously refractory to chemotherapy. The mechanisms contributing to this have not yet been defined and the contributions of drug efflux pumps, implicated in chemo-resistance of many other cancer types, have not been extensively investigated in melanoma. In this study, expression of multi-drug resistant (MDR1/P-gp and MRP-1) proteins was examined, by immunohistochemistry, in archival specimens from 134 melanoma patients. This included 92 primary tumours and 42 metastases. On assessing all specimens, MRP-1 and MDR1/P-gp expression was found to be common, with the majority (81%) of melanomas expressing at least one of these efflux pumps. Although there is significant association between expression of these pumps (P=0.007), MRP-1 was found to be the predominant (67% of cases) form detected. χ2 analysis showed significant associations between expression of MRP-1 and/or MDR1/P-gp and the aggressive nature of this disease specifically increased Breslow's depth, Clark's level and spread to lymph nodes. This association with aggressiveness and spread is further supported by the observation that a significantly higher percentage of metastases, than primary tumours, express MRP-1 (91% vs 57%; PP=0.010). The predominant expression of these pumps and, in particular, MRP-1 suggests that they may be important contributors to the inherent aggressive and resistant nature of malignant melanoma.Keywords
This publication has 21 references indexed in Scilit:
- Genetic risk factors for melanomaHuman Genetics, 2009
- Novel therapeutic agents under investigation for malignant melanomaExpert Opinion on Investigational Drugs, 2003
- Adjuvant Therapy in MelanomaOncology Research and Treatment, 2003
- Combination Chemotherapy with Docetaxel and Irinotecan in Metastatic Malignant MelanomaClinical Oncology, 2003
- Low-dose continuous chemotherapy for metastatic melanomaMelanoma Research, 2003
- Malignant melanoma: current state of primary and adjuvant treatmentCritical Reviews in Oncology/Hematology, 2003
- A New Monoclonal Antibody, P2A8(6), that Specifically Recognizes a Novel Epitope on the Multidrug Resistance-Associated Protein 1 (MRP1), but not on MRP2 nor MRP3Hybridoma and Hybridomics, 2001
- Induction of P-glycoprotein expression on the plasma membrane of human melanoma cells.2000
- Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cellsInternational Journal of Cancer, 1997
- Membrane transport proteins associated with drug resistance expressed in human melanoma.1995